27 completed, 7 terminated, 5 unknown, 3 withdrawn. 11 Phase 4, 10 Phase 2, 9 Phase 3, 6 Not applicable, 4 Phase 1.
Follow pegaptanib: new trials by email Literature Review of pegaptanib trials Research Report on pegaptanib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cohort Study of the Clinical Course of Macular Diseases in Kagawa ranibizumab, aflibercept, pegaptanib, verteporphin - Macular Disease | Phase 4 | Unknown | Kagawa University | 1000 | 2014-12-01 | 2018-03-07 |
| Cohort Study of the Clinical Course of Macular Diseases in Japanese ranibizumab, aflibercept, pegaptanib, verteporphin - Macular Disease | Unknown | Kyoto University, Graduate School of Medicine | 1000 | 2014-03-01 | 2016-09-23 | |
| A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy Macugen, Sham - Proliferative Diabetic Retinopathy | Phase 3 | Withdrawn | Greater Houston Retina Research | 2012-04-01 | 2014-03-05 | |
| A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy Macugen (Pegaptanib Sodium) - PDR | Phase 1 | Completed | Retina Institute of Hawaii | 5 | 2011-04-01 | 2011-12-07 |
| Intravitreal Macugen for Ischaemic Diabetic Macular Oedema Intravitreal injection of pegaptanib sodium - Diabetic Macular Oedema | Phase 4 | Completed | University of Oxford | 30 | 2011-01-01 | 2014-12-24 |
| Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema pegaptanib sodium - Anti- VGF Inhibitor, Diabetic Macular Edema | Phase 3 | Completed | Pfizer | 46 | 2011-01-01 | 2013-09-06 |
| Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia Intravitreal Pegaptanib - Myopic Choroidal Neovascular Membrane | Not applicable | Withdrawn | L.V. Prasad Eye Institute | 2010-12-01 | 2015-09-02 | |
| A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema pegaptanib sodium, sham injection - Macular Edema, Diabetic Mellitus | Phase 3 | Completed | Pfizer | 243 | 2010-05-01 | 2013-08-23 |
| Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium pegaptanib sodium injection - Age-Related Macular Degeneration, Retinal Vein Occlusion | Phase 4 | Completed | Bausch & Lomb Incorporated | 131 | 2010-04-22 | 2021-01-08 |
| Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Macugen® pegaptanib sodium - Diabetic Macular Edema | Phase 4 | Completed | Valley Retina Institute | 72 | 2009-04-01 | 2013-07-16 |
| Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema Pegaptanib - Uveitis, Cystoid Macular Edema | Not applicable | Completed | Wake Forest University | 5 | 2009-03-01 | 2022-03-15 |
| Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration Pegaptanib sodium - Macular Degeneration | Completed | Pfizer | 3538 | 2008-11-01 | 2015-10-02 | |
| Subretinal Macugen® for Neovascular Age-Related Macular Degeneration Pegaptanib (Macugen®) - Age-related Macular Degeneration | Phase 3 | Unknown | Klinikum Ludwigshafen | 10 | 2008-11-01 | 2011-09-27 |
| The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion ranibizumab, bevacizumab or pegaptanib - Macular Degeneration, Regional Blood Flow | Not applicable | Terminated | Medical University of Vienna | 8 | 2008-03-01 | 2014-11-14 |
| Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice. pegaptanib sodium - Neovascular Age-related Macular Degeneration | Completed | Pfizer | 86 | 2008-03-01 | 2012-04-11 | |
| Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration. Macugen - Neovascular Age-related Macular Degeneration | Withdrawn | Pfizer | 2008-02-01 | 2015-03-05 | ||
| Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED) Macugen ® (pegaptanib sodium) - Proliferative Diabetic Retinopathy | Phase 4 | Unknown | Valley Retina Institute | 30 | 2007-11-01 | 2011-12-06 |
| A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life. Macugen - Neovascular Age-related Macular Degeneration | Completed | Pfizer | 38 | 2007-11-01 | 2018-12-06 | |
| Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema) Macugen (pegaptanib), Macugen (Pegaptanib) - Proliferative Diabetic Retinopathy, Diabetic Macular Edema | Not applicable | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 28 | 2006-10-01 | 2012-04-19 |
| Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration Macugen - Macular Degeneration | Completed | Pfizer | 501 | 2006-08-01 | 2012-12-11 |
Showing 20 of 43. Sign in to see all of them.
Macular Degeneration (21) · Macular Edema (5) · Choroidal Neovascularization (3) · Retinal Vein Occlusion (3) · Diabetic Retinopathy (2) · Ischemia (1) · Retinal Diseases (1) · Uveitis (1) · Vitreous Hemorrhage (1)
Pfizer (13) · Eyetech Pharmaceuticals (9) · Johns Hopkins University (2) · Retina Institute of Hawaii (2) · Valley Retina Institute (2) · Barnes Retina Institute (1) · Bausch & Lomb Incorporated (1) · Greater Houston Retina Research (1) · Hermann Eye Center (1) · Kagawa University (1) · Klinikum Ludwigshafen (1) · Kyoto University, Graduate School of Medicine (1) · L.V. Prasad Eye Institute (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Medical University of Vienna (1)
United States (19) · Japan (5) · Austria (4) · France (4) · Germany (4) · Greece (4) · United Kingdom (4) · Belgium (3) · Canada (3) · Czechia (3) · Denmark (3) · Italy (3) · Spain (3) · Finland (2) · India (2)
Akiataka Tsujikawa, MD (1) · Diana V. Do, MD (1) · Gaurav K Shah, MD (1) · Ilse Krebs, MD (1) · James C Major, MD (1) · John A Wells, III, MD (1) · Lars-Olof Hattenbach, MD (1) · Mandeep Kaur, M.D. (1) · Michael D Bennett, MD (1) · Nagahisa Yoshimura, MD (1) · Oliver D. Schein, MD, MPH, MBA (1) · Raja Narayanan, MD (1)
PMID 19365011, PMID 20472746, PMID 21896838, PMID 22872673, PMID 24997182, PMID 25187694, PMID 37260074